The name of the drug has not been specified. It is known that it is based on virus-like particles, but does not contain genetic material, but mimics it. The vaccine will be tested in injectable intramuscular and intranasal forms.
The contractor is RIK-Pharma. The Gamaleya Center signed a contract with the company for 8,240,000 rubles.